[WAN, Zehong 万泽红, FENG, Jiaquan 冯加权, WU, Yongqi 吴永奇, QIN, Jun 秦俊, ZHOU, Bingcheng 周炳城, HU, Zhijing 胡志京, JIANG, Xinjian 姜新剑, FENG, Zijin 冯子晋] Building 12, No. 356, Zhengbo Road 中国上海市中国（上海）自由贸易试验区临港新片区正博路356号12幢, Shanghai 201208Lin-Gang Special Area of China(Shanghai) Pilot Free Trade ZoneShanghai 201208;No.18, Yangshan Road, Economic Development Zone 中国江苏省徐州市经济技术开发区杨山路18号, Jiangsu 221000Xuzhou, Jiangsu 221000 The present invention relates to a heterocyclic substituted fused γ-carboline derivative, a preparation method therefor, an intermediate thereof and use thereof. The heterocyclic substituted fused γ-carboline derivative has a compound structure as represented by formula (I). Such compound can be used for preparing a medicament for treating neuropsychiatric diseases. The present invention relates to a heterocyclic substituted fused γ-carboline derivative, a preparation method therefor, an intermediate thereof and use thereof. The heterocyclic substituted fused γ-carboline derivative has a compound structure as represented by formula (I). Such compound can be used for preparing a medicament for treating neuropsychiatric diseases.

[FENG, Jiaquan 冯加权, ZOU, Yuanhai 邹元海, WAN, Zehong 万泽红] Building 12, No. 356, Zhengbo Road, Lin-gang Special Area Of China (Shanghai) Pilot Free Trade Zone 中国上海市浦东新区中国（上海）自由贸易试验区临港新片区正博路356号12幢, Shanghai 201208Shanghai 201208;No.18, Yangshan Road, Economic Development Zone 中国江苏省徐州市经济开发区杨山路18号, Jiangsu 221000Xuzhou, Jiangsu 221000 The present invention relates to a benzo-ring-containing derivative, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (Ia), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof as a GABA receptor agonist in the field of the central nervous system, specifically in inducing and maintaining anesthesia of mammals.

[FENG, Jiaquan 冯加权, DENG, Xinshan 邓新山, WAN, Zehong 万泽红] Building 12, No. 356, Zhengbo Road, Lin-gang Special Area Of China (Shanghai) Pilot Free Trade Zone 中国上海市浦东新区中国（上海）自由贸易试验区临港新片区正博路356号12幢, Shanghai 201208Shanghai 201208;No.18, Yangshan Road, Economic Development Zone 中国江苏省徐州市经济开发区杨山路18号, Jiangsu 221000Xuzhou, Jiangsu 221000 The present invention relates to an oxaspiro derivative, and a preparation method therefor and the use thereof. Specifically, provided are a compound as represented by general formula (I), a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor, the use thereof for activating the activity of an opioid receptor, and the use thereof in the preparation of an analgesic drug.

[QIN, Jun 秦俊, WU, Yongqi 吴永奇, FENG, Jiaquan 冯加权, HUANG, Wei 黄伟, ZOU, Yuanhai 邹元海, ZHOU, Bingcheng 周炳城, HU, Zhijing 胡志京, JIANG, Xinjian 姜新剑, WAN, Zehong 万泽红] Building 12, No. 356, Zhengbo Road, Lin-gang Special Area Of China (Shanghai) Pilot Free Trade Zone 中国上海市中国（上海）自由贸易试验区临港新片区正博路356号12幢, Shanghai 201208Shanghai 201208;No.18, Yangshan Road, Economic Development Zone 中国江苏省徐州市经济开发区杨山路18号, Jiangsu 221000Xuzhou, Jiangsu 221000 Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing and/or treating central nervous system diseases related to 5-hydroxytryptamine receptors and/or trace amine-related receptors and/or dopamine receptors in mammals. Provided are a spiro-containing derivative, and a preparation method therefor and the use thereof. In particular, provided are a compound as shown in general formula (I), and a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug for preventing and/or treating central nervous system diseases related to 5-hydroxytryptamine receptors and/or trace amine-related receptors and/or dopamine receptors in mammals.

[DONG, Jiaqiang 董加强, FENG, Jiaquan 冯加权, WANG, Tielin 王铁林] Building 1 And 1st -3rd Floor, Building 2, NO.85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area 中国上海市浦东新区自由贸易试验区法拉第路85号1幢、2幢1-3层, Shanghai 201210Shanghai 201210;Road Luo 7, National High & New Technology Industries Development Zone 中国山东省临沂市国家高新技术产业开发区罗七路, Shandong 276017Linyi, Shandong 276017 A heterocyclic compound shown in formula I and application thereof as a Trk kinase inhibitor.

[FENG, Jiaquan 冯加权, DONG, Jiaqiang 董加强, WANG, Tie-Lin 王铁林] Building 1 and 1st -3rd Floor, Building 2 中国上海市浦东新区自由贸易试验区法拉第路85号1幢、2幢1-3层, Shanghai 201210No. 85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Pudong New AreaShanghai 201210;Road Luo 7 中国山东省临沂市国家高新技术产业开发区罗七路, Shandong 276017National High & New Technology Industries Development ZoneLinyi, Shandong 276017 Disclosed are a tricyclic compound, a preparation method therefor, and an intermediate and use thereof. Such compounds have the activity of inhibiting tropomyosin receptor kinase and can be used to treat cancers, pain, neurological diseases, autoimmune diseases, inflammation and other diseases.

[FENG, Jiaquan 冯加权, SHI, Junjie 石俊杰, ZOU, Yuanhai 邹元海, WAN, Zehong 万泽红] Building 12, No. 356, Zhengbo Road, Lin-gang Special Area Of China (Shanghai) Pilot Free Trade Zone 中国上海市浦东新区自由贸易试验区临港新片区正博路356号12幢, Shanghai 201208Pudong New Area, Shanghai 201208;No.18, Yangshan Road, Economic Development Zone 中国江苏省徐州市经济技术开发区杨山路18号, Jiangsu 221000Xuzhou, Jiangsu 221000 The present invention relates to a steroid compound, a preparation method therefor, and a use thereof. Specifically, the present invention provides a compound as shown in general formula (I), a stereoisomer or pharmaceutically-acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a GABAA receptor modulator in the treatment of CNS-related diseases. The present invention relates to a steroid compound, a preparation method therefor, and a use thereof. Specifically, the present invention provides a compound as shown in general formula (I), a stereoisomer or pharmaceutically-acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a GABAA receptor modulator in the treatment of CNS-related diseases.

[WEI, Guoping 魏国平, HU, Yunjin 胡允金, LIU, Le 刘乐, YOU, Zhixian 游志先, LI, Xiaolong 李小龙, LU, Tingting 陆婷婷, WU, Guosheng 吴国胜, FENG, Jiaquan 冯加权, DONG, Jiaqiang 董加强, WANG, Tie-Lin 王铁林, YANG, Hua 阳华] Building 1 and 1st -3rd Floor, Building 2, No.85 Faladi Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area 中国上海市浦东新区自由贸易试验区法拉第路85号1幢、2幢1-3层, Shanghai 201210Shanghai 201210;Road Luo 7, National High & New Technology Industries Development Zone 中国山东省临沂市国家高新技术产业开发区罗七路, Shandong 276017Linyi, Shandong 276017 Disclosed are a five-membered heterocyclo-pyrimidine compound, a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition for improving the activity of TLR 7. The structure of the compound is as shown in the following formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R9, X, Y, Z, A and B are as defined in the description herein. The compound or pharmaceutical composition of the present invention, as a TLR7 agonist, can be used for treating diseases such as liver related diseases, tumors or AIDS.

[HU, Yunjin 胡允金, LIU, Le 刘乐, WEI, Guoping 魏国平, YOU, Zhixian 游志先, LI, Xiaolong 李小龙, WU, Guosheng 吴国胜, FENG, Jiaquan 冯加权, DONG, Jiaqiang 董加强, WANG, Tie-Lin 王铁林, YANG, Hua 阳华] Building 1 and 1st -3rd Floor, Building 2 中国上海市浦东新区自由贸易试验区法拉第路85号1幢、2幢1-3层, Shanghai 201210No. 85 Faladi Road, China (Shanghai) Pilot Free Trade ZonePudong New AreaShanghai 201210;Road Luo 7 中国山东省临沂市国家高新技术产业开发区罗七路, Shandong 276017National High & New Technology Industries Development ZoneLinyi, Shandong 276017 The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph, a tautomer, an isotope compound, and a metabolite or a prodrug thereof for treating diseases that respond to TLR 7 receptor activation. (I) The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph, a tautomer, an isotope compound, and a metabolite or a prodrug thereof for treating diseases that respond to TLR 7 receptor activation. (I)

[CAO, Jianhua 曹建华, GENG, Meiyu 耿美玉, HUANG, Min 黄敏, JIANG, Lei 江磊, LI, Lei 李磊, TANG, Shuai 唐帅, FENG, Jiaquan 冯加权, YANG, Xiaotong 杨晓彤, ZHENG, Hongyan 郑红艳, WU, Yingxiong 吴英雄, REN, Fangfang 任芳芳, DING, Jian 丁健] 555 Zu Chong Zhi Road, Zhang Jiang, Pudong 中国上海市浦东张江祖冲之路555号, Shanghai 201203Shanghai 201203;Room 208, Section 103, No. 6 Building, No. 421 Niudun Rd, Pudong New Area 中国上海市浦东新区中国（上海）自由贸易试验区牛顿路421号6幢103部位208室, Shanghai 201203Shanghai 201203 Disclosed are a compound having ERK kinase inhibitory activity, a method for preparation thereof, and a use thereof; in particular, disclosed are the compound having formula I, a stereoisomer thereof, a racemate thereof, or pharmaceutically acceptable salt thereof, and an application of said compound in preparing a pharmaceutical used for preventing and treating illness related to ERK kinase.